GlassScriptPhysician profile
Grant Stephen Parkins
NPI 1598769424
$2,276.99
in general payments reported to CMS, 2019-2025
28 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $77.16 · 2021: $156 · 2022: $336 · 2023: $222 · 2024: $309 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $305.68 | 2019-2024 | |
| Pfizer INC. | $289.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $217.95 | 2019-2022 | |
| Novo Nordisk INC | $208.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $199.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $142.76 | 2019-2023 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $101.74 | 2019-2024 | Vaxneuvance, Capvaxive |
| Amgen INC. | $85.29 | 2019-2023 | Evenity, Prolia |
| Dexcom, INC. | $79.42 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $77.05 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $69.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.19 | 2022-2023 | Trelegy Ellipta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.12 | 2019-2022 | |
| Medtronic, INC. | $43.47 | 2024 | Closurefast |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $34.70 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $32.50 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.33 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $31.02 | 2019 | |
| Abbvie INC. | $26.57 | 2022 | |
| Averitas Pharma INC. | $24.77 | 2023 | Qutenza |
| Genentech USA, INC. | $19.17 | 2019 | |
| Verona Pharma, INC. | $19.02 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $18.98 | 2025 | Rexulti |
| Pulmonx Corporation | $17.49 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Teva Pharmaceuticals USA, INC. | $15.15 | 2023 | Austedo Xr |
| Exact Sciences Corporation | $13.50 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Parkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.